Shares of this biotech company can rally nearly 60% as use of its gene therapy to treat herpes simplex virus grows, Goldman Sachs says.
You are here: Home / Buy this little-known biotech stock set to rally nearly 60% as use of gene therapy grows, Goldman Sachs says